The Life Sciences team advised Dualitas Therapeutics, Inc. (“Dualitas”) on a research collaboration and license agreement with Roche to advance novel bispecific antibodies for immunology and inflammation (I&I) diseases using Dualitas’ DualScreen™ Bispecific Discovery Engine. In what is believed to be one of the largest-scale bispecific discovery endeavors, Dualitas will functionally screen over 300,000 novel bispecific combinations to discover and develop bispecific antibody therapeutics. Roche will be responsible for all subsequent preclinical development, regulatory, manufacturing, and commercial activities.
Under the terms of the agreement, Dualitas will receive a $36.5 million upfront payment and may receive additional research, development, and commercial milestone payments for a potential total deal value of up to $1 billion, in addition to tiered royalties.
Dualitas Therapeutics, Inc., is a biotechnology company pioneering next-generation bispecific antibody therapies for I&I. Dualitas’ portfolio, built from its DualScreen™ discovery engine, includes development candidate DTX-102 in rheumatoid arthritis, DTX-103 in allergic disease, and DTX-101 in dermatologic and gastrointestinal autoimmune disease, alongside additional discoveries based on cell-surface proximity biology and novel co-target pairing. While advancing its own pipeline, Dualitas offers a variety of strategic collaboration opportunities to extend the impact of its discovery capabilities, ranging from existing pipeline programs to identifying de novo BsAbs to establishing programs in disease areas beyond I&I.
The Goodwin team was led by Erini Svokos and Chris Zhong.
For more information on the deal, please read the press release and see coverage in Endpoints, BioPharma, and FirstWord.